Nectin Therapeutics Funding: $25M Raised, Series A (2024)
Nectin Therapeutics is based in Fort Lee. It has raised $25M in total funding. Latest round: Series A.
Nectin Therapeutics funding overview
Nectin Therapeutics is based in Fort Lee. Nectin Therapeutics has raised $25M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in May 2024. The round record for Nectin Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Israel Biotech Fund (IBF), Peregrine Ventures, aMoon Fund, Guangzhou-Israel Biotechnology Fund (GIBF), Cancer Focus Fund, Integra Holdings. 6 distinct backers are named across the disclosed rounds.
Nectin Therapeutics at a glance
Total raised
$25M
Latest round
Series A
Latest round date
May 2024
Headquarters
Fort Lee
Notable investors
Israel Biotech Fund (IBF), Peregrine Ventures, aMoon Fund, Guangzhou-Israel Biotechnology Fund (GIBF), Cancer Focus Fund, Integra Holdings
Frequently asked about Nectin Therapeutics funding
How much has Nectin Therapeutics raised?
Nectin Therapeutics has raised $25M in total disclosed funding across the rounds on record.
Who has invested in Nectin Therapeutics?
Israel Biotech Fund (IBF), Peregrine Ventures, aMoon Fund, Guangzhou-Israel Biotechnology Fund (GIBF), Cancer Focus Fund, Integra Holdings are named among the investors backing Nectin Therapeutics.
What was the latest Nectin Therapeutics funding round?
The most recent disclosed round is a Series A, announced in May 2024.
Where is Nectin Therapeutics based?
Nectin Therapeutics is based in Fort Lee.
When did Nectin Therapeutics last raise?
The last disclosed Nectin Therapeutics round closed in May 2024 at Series A.
We update the Nectin Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Fort Lee and their backers are listed below.
